Project Grant HT94252410147
Award Date
6/1/24
Completion Date
5/31/27
Dollars Obligated
$1.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94103, USA
Similar Awards
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,967,999.00 to The Regents of the University of California, San Francisco (UCSF) to develop a CD46 targeted antibody fragment radiopharmaceutical therapy for the treatment of prostate cancer. The award period runs from July 1, 2025 to June 30, 2028. UCSF, a leading academic medical and research institution, will leverage its expertise in biomedical...
The University of California, San Francisco (UCSF) has been awarded a $1,202,087 federal Project Grant from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to investigate SSTR1 as a novel biomarker and therapeutic target in advanced prostate cancer. The award, effective July 1, 2024 through June 30, 2028, will enable UCSF researchers to conduct innovative scientific studies to develop new treatments for this challenging disease. As a leading academic...
The Regents of the University of California, San Francisco (UCSF) has been awarded a $595,160 Project Grant by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to translate a first-in-class PET radiotracer to assess ferroaddiction as a therapeutic vulnerability in advanced prostate cancer. The 3-year award, effective July 1, 2024, supports innovative biomedical research aimed at developing new diagnostic and treatment approaches for military personnel...
This $1,211,127 Project Grant awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a research project by the University of California, San Francisco (UCSF) to investigate the importance of immune responses to prostate tumor antigens primed by a combination of radiation and immunotherapy. The 4-year project aims to advance understanding of how to leverage the body's immune system to improve treatments for prostate cancer. As...
The Defense Health Agency awarded a $1,453,500.00 Project Grant to The Regents of the University of California, San Francisco (UCSF) under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, commencing on June 20, 2023, will support UCSF's research to profile and eliminate tumor subclones resistant to radioligand therapy. Through this project, UCSF aims to transform health care for Service Members and the American public by developing innovative and...
The Department of the Army Medical Command awarded a $161,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Regents of the University of California, San Francisco (UCSF) to conduct research on "Deciphering Translational Control of Androgen Receptor in Prostate Cancer". The grant project will run from April 1, 2024 to March 31, 2026. As a leading academic medical center and research institution, UCSF has extensive expertise in federal...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,615,000.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at "DISCOVERING TRANSCRIPTIONAL DRIVERS OF THERAPY-RESISTANT METASTATIC PROSTATE CANCER". The award period runs from May 1, 2024 to April 30, 2027. As a leading academic medical center, UCSF has a strong track record of...
This Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,228,594.00 to the Regents of the University of California, San Francisco (UCSF) for research on bispecific antibody-drug conjugates against emerging targets in metastatic lethal prostate cancer. The award period is from April 15, 2024 to April 14, 2027. As a leading academic medical center and research institution, UCSF will leverage its...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,226,730.00 to The Regents of the University of California, San Francisco (UCSF) to investigate the canonical Polycomb Repressive Complex 1 (cPRC1) as a potential mechanism of resistance to the prostate cancer drug enzalutamide in advanced prostate cancer. The award period runs from August 1, 2025 to July 31, 2029. UCSF, a leading academic medical...
This $854,219 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the University of California, San Francisco (UCSF) to translate a first-in-class PET radiotracer for assessing ferroaddiction as a therapeutic vulnerability in advanced prostate cancer. The 3-year project, running from July 2024 to June 2027, aims to develop this innovative molecular imaging approach to improve treatment selection...